Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)

University Hospital Center (CHU) Dijon Bourgogne

Status: Completed

Conditions: Solid Tumor; Neoplasia; Horton's Disease; Infectious Disease; Hemopathy

Treatments: Other: 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse); Other: 1 blood sample

Study type: Observational

Funder types: Other

Identifiers

NCT02065297

AUDIA-SAMSON HORTON TH17

Details and patient eligibility

About

The aim of this open, controlled, multicentre biomedical research study is to identify new markers specifically associated with Horton's disease. This would make it possible to improve the diagnosis and management of this disease.

Participation consists in taking one or several blood samples depending on the group patients/controls.

Enrollment: 143 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Patients

• Patients who have provided written informed consent
• Patients with national health insurance cover
• Age: 50 to 90 years

Patients with Horton' s disease :

• at the diagnosis, before any treatment
• or in remission
• or in relapse

Patients with an infectious disease :

• Bacteriologically or radiologically confirmed
• Presenting an inflammatory syndrome defined by :
• CRP ≥ 10 mg / L
• and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1

Patients with neoplasia ( solid tumour or hemopathy ) :

• At the diagnosis, before treatment by chemotherapy
• Presenting an inflammatory syndrome defined by:
• CRP ≥ 10 mg / L
• and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1

Controls :

These are healthy volunteers recruited among blood donators at Dijon CHU, voluntary hospital personnel ( nurses, doctors and secretaries ), patients at the EPHAD ( Champmaillot centre for geriatric patients ) and patients without infectious, inflammatory, or auto-immune disease ( CRP < 5mg / L ) or cancer recruited from the investigating departments of Dijon CHU. They will be matched for age and sex.

• Age: 18 - 90 years
• Patients with national health insurance cover
• who have provided written informed consent
• Absence of an inflammatory syndrome ( CRP < 5 mg / L )

Exclusion Criteria :

• Any patient who does not meet the inclusion criteria

Trial design

143 participants in 4 patient groups

Horton's disease

Treatment:

Other: 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)

Infectious disease

Treatment:

Other: 1 blood sample

Neoplasia

Treatment:

Other: 1 blood sample

Control

Treatment:

Other: 1 blood sample